Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Prolia & Xgeva (denosumab).This product consists of: Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.Projec ...